Harnessing Nanocarriers to Modulate Gut Inflammation: A New Era in IBD Management.

PMID 41968553 | DOI 10.2174/0127722708408084251209145952 · Recent advances in inflammation & allergy drug discovery · 2026

View on PubMed ↗

Inflammatory bowel disease (IBD) is a chronic inflammatory condition affecting the gastrointestinal tract, primarily including Crohn's disease and ulcerative colitis. Current treatments rely heavily on synthetic medications and monoclonal antibodies. While these are effective for some patients, they often cause serious side effects, incur high costs, and can lead to complications with long-term use. Consequently, there is growing interest in exploring alternative and complementary therapies. Natural biomolecules derived from plants and animals have demonstrated promising anti-inflammatory and immunomodulatory effects in both in vitro and in vivo studies, offering a potentially safer and more sustainable approach to managing IBD. Nanotechnology is driving significant progress in the diagnosis and treatment of IBD. With biosensors and advanced imaging agents, the disease can be detected and monitored more accurately, enabling earlier and more precise diagnoses. Additionally, nanoparticles are being extensively studied as drug delivery systems because they can improve targeted therapy, protect drugs from degradation, and reduce systemic toxicity. However, challenges remain, including premature drug release, limited targeting efficiency, and undesired immune reactions. Although several clinical trials are ongoing, only a few nanoparticle-based treatments have achieved successful outcomes. This review aims to highlight recent advances in nanoparticle-mediated diagnosis and therapy for IBD, emphasizing the opportunities, challenges, and future directions in this field.